Conditions: Allergies
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 217
Healthy volunteers: yes

Brief summary:
This was a randomized, open-label, 2-way cross-over study, comparing desloratadine RediTab 2.5 mg to a marketed chewable antihistamine oral medication (Zyrtec® 5 mg

Chewable Tablet). Subject preference for one product or the other was determined. Acceptability of product attributes (Taste and Feeling in the Mouth) was rated using a "smile" face scale.

Detailed description:

Arms:
arm 1: Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference. arm 2: Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.

Interventions: intervention 1: Desloratadine intervention 2: Zyrtec® (cetirizine)
Intervention descriptions: intervention 1: SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day intervention 2: Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day

Protocol document: